Vitamin D supplementation does not prevent the testosterone decline in males with advanced heart failure: the EVITA trial.

Purpose: Observational studies indicate a positive association between circulating 25-hydroxyvitamin D (25OHD) and testosterone (T) concentrations. Because low 25OHD concentrations and T deficiency are considered to be a generalized phenomenon in patients with advanced heart failure (HF), we aimed t...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nutrition Vol. 58; no. 2; pp. 673 - 681
Autores principales: Zittermann, Armin, Ernst, Jana B., Prokop, Sylvana, Fuchs, Uwe, Dreier, Jens, Kuhn, Joachim, Knabbe, Cornelius, Berthold, Heiner K., Gouni-Berthold, Ioanna, Gummert, Jan F., Börgermann, Jochen, Pilz, Stefan
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Springer Nature Mar2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135579580&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 135579580
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14366207
        CR0
      jtl: European Journal of Nutrition
      issn: 14366207
      maglogo: N
    pubinfo:
      dt: Mar2019
      vid: 58
      iid: 2
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        135579580
        135579580
        135579580
        10.1007/s00394-018-1666-5
        135579580
      ppf: 673
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Vitamin D supplementation does not prevent the testosterone decline in males with advanced heart failure: the EVITA trial.
      aug:
        au:
          Zittermann, Armin
          Ernst, Jana B.
          Prokop, Sylvana
          Fuchs, Uwe
          Dreier, Jens
          Kuhn, Joachim
          Knabbe, Cornelius
          Berthold, Heiner K.
          Gouni-Berthold, Ioanna
          Gummert, Jan F.
          Börgermann, Jochen
          Pilz, Stefan
        affil: Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Georgstraße 11, 32545, Bad Oeynhausen, Germany
      sug:
        subj:
          Vitamin D Therapeutic Use
          Dietary Supplementation
          Testosterone
          Heart Failure
          Human
          Male
          Nonexperimental Studies
          Randomized Controlled Trials
          Random Assignment
          Treatment Outcomes
          Confidence Intervals
          Sex Hormones
          Cholecalciferol Administration and Dosage
          Glycoproteins
          Male
      ab: Purpose: Observational studies indicate a positive association between circulating 25-hydroxyvitamin D (25OHD) and testosterone (T) concentrations. Because low 25OHD concentrations and T deficiency are considered to be a generalized phenomenon in patients with advanced heart failure (HF), we aimed to investigate whether vitamin D supplementation has beneficial effects on T indices in these patients. Methods: In a pre-specified secondary analysis of the EVITA (effect of vitamin D on mortality in heart failure) randomized controlled trial, we analyzed in male subjects with 25OHD concentrations < 75 nmol/L the effect of a daily vitamin D3 supplement of 4000 IU for 3 years (n = 71) vs. placebo (n = 62) on total T (TT), sex hormone-binding globulin (SHBG), free T (fT), and bioactive T (BAT). We assessed changes from baseline until study termination and between-group differences at study termination. Results: 25OHD increased in the placebo group from 36.6 nmol/L by 9.2 nmol/L (95% CI 3.2–15.1 nmol/L; P = 0.003) and in the vitamin D group from 36.5 nmol/L by 63.9 nmol/L (95% CI 52.6–75.3 nmol/L; P < 0.001), with a significant between-group difference at study termination (P < 0.001). TT and SHBG concentrations did not change significantly, neither in the placebo group nor in the vitamin D group (P = 0.845–0.082), but concentrations of fT and BAT declined significantly in both groups (P = 0.025–0.008). At study termination, there were no between-group differences in TT (P = 0.612), SHBG (P = 0.393), fT (P = 0.861), or BAT (P = 0.960). Conclusions: In male patients with advanced HF and low 25OHD concentrations, a daily vitamin D3 supplement of 4000 IU for 3 years did not prevent the decline in testosterone indices.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N